Health Catalyst (NASDAQ:HCAT) Price Target Raised to $9.00 at Stephens

Health Catalyst (NASDAQ:HCAT) had its price target lifted by Stephens from $7.00 to $9.00 in a research report report published on Thursday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

HCAT has been the subject of a number of other research reports. Piper Sandler reduced their price target on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 26th. Royal Bank of Canada increased their price target on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th. Evercore ISI upped their price objective on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Finally, JPMorgan Chase & Co. upped their price objective on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Health Catalyst has an average rating of “Moderate Buy” and an average price target of $11.71.

Health Catalyst Price Performance

Shares of NASDAQ HCAT opened at $7.65 on Thursday. Health Catalyst has a 1-year low of $5.42 and a 1-year high of $11.41. The business has a 50-day moving average of $8.16 and a 200-day moving average of $7.23. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The company has a market capitalization of $465.50 million, a price-to-earnings ratio of -5.67 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The business had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.22) EPS. On average, equities analysts anticipate that Health Catalyst will post -0.35 EPS for the current fiscal year.

Insider Transactions at Health Catalyst

In other news, COO Daniel Lesueur sold 8,137 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46. Following the sale, the chief operating officer now directly owns 140,108 shares in the company, valued at approximately $1,062,018.64. This represents a 5.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now owns 255,881 shares in the company, valued at $1,847,460.82. The trade was a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 34,068 shares of company stock worth $257,555. 2.50% of the stock is currently owned by company insiders.

Institutional Trading of Health Catalyst

Large investors have recently added to or reduced their stakes in the business. Quest Partners LLC acquired a new stake in Health Catalyst in the 3rd quarter valued at approximately $34,000. Nisa Investment Advisors LLC increased its position in Health Catalyst by 461.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after acquiring an additional 5,232 shares during the period. Quarry LP increased its position in Health Catalyst by 59.4% in the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after acquiring an additional 2,610 shares during the period. nVerses Capital LLC acquired a new stake in Health Catalyst in the 3rd quarter valued at approximately $59,000. Finally, Perfromance Wealth Partners LLC acquired a new stake in Health Catalyst in the 2nd quarter valued at approximately $64,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.